Cost effectiveness of contraceptives in the United States



      The study was conducted to estimate the relative cost effectiveness of contraceptives in the United States from a payer's perspective.


      A Markov model was constructed to simulate costs for 16 contraceptive methods and no method over a 5-year period. Failure rates, adverse event rates and resource utilization were derived from the literature. Sensitivity analyses were performed on costs and failure rates.


      Any contraceptive method is superior to ���no method���. The three least expensive methods were the copper-T intrauterine device (IUD) (US$647), vasectomy (US$713) and levonorgestrel (LNG)-20 intrauterine system (IUS) (US$930). Results were sensitive to the cost of contraceptive methods, the cost of an unintended pregnancy and plan disenrollment rates.


      The copper-T IUD, vasectomy and the LNG-20 IUS are the most cost-effective contraceptive methods available in the United States. Differences in method costs, the cost of an unintended pregnancy and time horizon are influential factors that determine the overall value of a contraceptive method.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Finer L.B.
        • Henshaw S.K.
        Disparities in rates of unintended pregnancy in the United States, 1994 and 2001.
        Perspect Sex Reprod Health. 2006; 38: 90-96
        • Trussell J.
        The cost of unintended pregnancy in the United States.
        Contraception. 2007; 75: 168-170
        • Mosher W.D.
        • Martinez G.M.
        • Chandra A.
        • Abma J.C.
        • Willson S.J.
        Use of contraception and use of family planning services in the United States: 1982���2002.
        Adv Data. 2004; : 1-36
        • Chiou C.F.
        • Trussell J.
        • Reyes E.
        • et al.
        Economic analysis of contraceptives for women.
        Contraception. 2003; 68: 3-10
        • Trussell J.
        • Koenig J.
        • Ellertson C.
        • Stewart F.
        Preventing unintended pregnancy: the cost-effectiveness of three methods of emergency contraception.
        Am J Public Health. 1997; 87: 932-937
        • Chandra A.
        • Martinez G.M.
        • Mosher W.D.
        • Abma J.C.
        • Jones J.
        Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth.
        Vital Health Stat 2. 2005; 23: 1-160
        • Hatcher R.A.
        • Trussell J.
        • Nelson A.L.
        • Cates W.
        • Stewart F.H.
        • Kowal D.
        Contraceptive technology.
        19th rev. ed. Ardent Media, New York (NY)2007
        • Backman T.
        • Rauramo I.
        • Huhtala S.
        • Koskenvuo M.
        Pregnancy during the use of levonorgestrel intrauterine system.
        Am J Obstet Gynecol. 2004; 190: 50-54
        • Backman T.
        • Huhtala S.
        • Blom T.
        • Luoto R.
        • Rauramo I.
        • Koskenvuo M.
        Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation-wide study of 17,360 users.
        BJOG. 2000; 107: 335-339
        • Westrom L.
        • Bengtsson L.P.
        • Mardh P.A.
        Incidence, trends, and risks of ectopic pregnancy in a population of women.
        Br Med J (Clin Res Ed). 1981; 282: 15-18
        • Croxatto H.B.
        • Makarainen L.
        The pharmacodynamics and efficacy of Implanon. An overview of the data.
        Contraception. 1998; 58: 91S-97S
        • Peterson H.B.
        • Xia Z.
        • Hughes J.M.
        • Wilcox L.S.
        • Tylor L.R.
        • Trussell J.
        The risk of ectopic pregnancy after tubal sterilization. U.S. Collaborative Review of Sterilization Working Group.
        N Engl J Med. 1997; 336: 762-767
        • Lahteenmaki P.
        • Rauramo I.
        • Backman T.
        The levonorgestrel intrauterine system in contraception.
        Steroids. 2000; 65: 693-697
        • Trussell J.
        • Leveque J.A.
        • Koenig J.D.
        • et al.
        The economic value of contraception: a comparison of 15 methods.
        Am J Public Health. 1995; 85: 494-503
        • Endrikat J.
        • Dusterberg B.
        • Ruebig A.
        • Gerlinger C.
        • Strowitzki T.
        Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study.
        Contraception. 1999; 60: 269-274
        • Jick S.S.
        • Kaye J.A.
        • Russmann S.
        • Jick H.
        Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
        Contraception. 2006; 73: 223-228
        • Fihn S.D.
        • Latham R.H.
        • Roberts P.
        • Running K.
        • Stamm W.E.
        Association between diaphragm use and urinary tract infection.
        JAMA. 1985; 254: 240-245
        • Audet M.C.
        • Moreau M.
        • Koltun W.D.
        • et al.
        Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial.
        JAMA. 2001; 285: 2347-2354
        • Barreiros F.A.
        • Guazzelli C.A.
        • de Araujo F.F.
        • Barbosa R.
        Bleeding patterns of women using extended regimens of the contraceptive vaginal ring.
        Contraception. 2007; 75: 204-208
        • Hooton T.M.
        • Scholes D.
        • Hughes J.P.
        • et al.
        A prospective study of risk factors for symptomatic urinary tract infection in young women.
        N Engl J Med. 1996; 335: 468-474
        • Fihn S.D.
        • Boyko E.J.
        • Normand E.H.
        • et al.
        Association between use of spermicide-coated condoms and Escherichia coli urinary tract infection in young women.
        Am J Epidemiol. 1996; 144: 512-520
      1. Drug topics red book. Thomson Healthcare, Montvale (NJ)2007
      2. Cerner Multum��� Lexicon, 2007.

        • Wolters Kluwer Health
        Price Rx drug price and reference tool (Medi-Span Master Drug Database).
        (Available at) ([Accessed October 2007])
      3. Pharmacy directory: drug prices.
        (Available at) ([Accessed March 2008])
      4. Current procedural terminology (CPT). American Medical Association, Chicago (IL)2007
        • Marquette C.M.
        • Koonin L.M.
        • Antarsh L.
        • Gargiullo P.M.
        • Smith J.C.
        Vasectomy in the United States, 1991.
        Am J Public Health. 1995; 85: 644-649
        • MacKay A.P.
        • Kieke Jr., B.A.
        • Koonin L.M.
        • Beattie K.
        Tubal sterilization in the United States, 1994���1996.
        Fam Plann Perspect. 2001; 33: 161-165
      5. Ingenix DRG Expert. Ingenix, Eden Prairie (MN)2007
        • Finer L.B.
        • Henshaw S.K.
        Abortion incidence and services in the United States in 2000.
        Perspect Sex Reprod Health. 2003; 35: 6-15
        • Henshaw S.K.
        • Finer L.B.
        The accessibility of abortion services in the United States, 2001.
        Perspect Sex Reprod Health. 2003; 35: 16-24
        • Abortion Surveillance ��� United States
        Centers for Disease Control and Prevention. Surveillance summaries. MMWR Morb Mortal Wkly Rep. vol. 55, No. SS-11.
        (Available at) ([Accessed March 2008])
        • March of Dimes
        The healthcare costs of having a baby.
        (Available at) ([Accessed June 2008])
        • Machlin S.R.
        • Rohde F.
        Health care expenses for uncomplicated pregnancies. Research Findings No. 27.
        (Available at) ([Accessed March 2008])
        • Merrill C.
        • Steiner C.
        Hospitalizations related to childbirth, 2003. HCUP Statistical Brief #11. Agency for Healthcare Research and Quality, Rockville, MD.
        (Available at) ([Accessed November 2007])
        • Agency for Healthcare Research and Quality
        Healthcare Cost and Utilization Project (HCUP).
        (Available at) ([Accessed June 2008])
        • Baldaszti E.
        • Wimmer-Puchinger B.
        • Loschke K.
        Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena): a 3-year follow-up study.
        Contraception. 2003; 67: 87-91
      6. Trussell J, Koenig J, Stewart F, Darroch JE. Medical care cost savings from adolescent contraceptive use. Fam Plann Perspect 1997;29:248���255, 295.

        • National Collaborating Centre for Women & Children's Health
        Long-acting reversible contraception: the effective and appropriate use of long-acting reversible contraception.
        Royal College of Obstetricians and Gynecologists (RCOG), London (UK)2005
        • Mavranezouli I.
        The cost-effectiveness of long-acting reversible contraceptive methods in the UK: analysis based on a decision-analytic model developed for a National Institute for Health and Clinical Excellence (NICE) clinical practice guideline.
        Hum Reprod. 2008; 23: 1338-1345
        • Varney S.J.
        • Guest J.F.
        Relative cost effectiveness of Depo-Provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UK.
        Pharmacoeconomics. 2004; 22: 1141-1151
        • Phillips C.J.
        Economic analysis of long-term reversible contraceptives. Focus on Implanon.
        Pharmacoeconomics. 2000; 17: 209-221
      7. Trussell J, Vaughan B. Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999;31:64���72, 93.

        • Vaughan B.
        • Trussell J.
        • Kosta K.
        • Singh S.
        • Jones R.
        Discontinuation and resumption of contraceptive use: results from the 2002 National Survey of Family Growth.
        Contraception. 2008; 78: 271-283
        • Xiao B.
        • Wu S.C.
        • Chong J.
        • Zeng T.
        • Han L.H.
        • Luukkainen T.
        Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia.
        Fertil Steril. 2003; 79: 963-969
        • Trussell J.
        Overstating cost savings from contraceptive use.
        Eur J Contracept Reprod Health Care. 2008; 13: 219-221

      Linked Article